Colon and Rectal Cancer

The University of Chicago Medicine is ranked among the nation’s best hospitals for cancer care, according to U.S. News & World Report in its 2015-2016 “Best Hospitals” survey.

Our colon and rectal cancer program’s national reputation hinges on our ability to bring together the best minds in gastrointestinal disease and cancer care. Experts in medical and radiation oncology as well as colorectal surgery work in cohesion to craft the best possible treatment plan for patients.

In addition to our team of internationally recognized experts, our program offers the full array of today’s most advanced diagnostic and treatment options. When surgery is the recommended treatment, our surgeons are able to perform standard as well as minimally invasive procedures to resect colon and rectal cancers, including:

  • Sphincter-sparing procedures
  • Transanal endoscopic microsurgery
  • Colectomy
  • Abdominal perineal resection
  • Small bowel resection
  • Stoma creation
  • Laparoscopic or robotic surgery

In fact, some of our colorectal surgeons are considered leaders in robotic surgery, maintaining one of the busiest robotic colorectal surgery programs in the Chicagoland area.

In addition to these treatment options, the University of Chicago Medicine became one of the first institutions to utilize intraoperative radiotherapy (IORT) to help minimize the risk of cancer recurrence. The radiation therapy is delivered intraoperatively, after the patient’s tumor has been resected. In addition to recurrence prevention, IORT offers a host of other benefits, including less external radiation and tissue damage.

Our surgeons are also a part of the Alliance for Clinical Trials in Oncology, which allows patients access to new and emerging therapies to treat colon and rectal cancer.

Cancer treatment at the University of Chicago Medicine would not be complete without our team’s commitment to post-operative support. This includes a team of nutritionists and social workers who work with patients to maintain quality of life after their cancer treatment.